IL111790A - Use of benzo [B] thiopines in the preparation of anti-amyloidogenic drugs - Google Patents
Use of benzo [B] thiopines in the preparation of anti-amyloidogenic drugsInfo
- Publication number
- IL111790A IL111790A IL11179094A IL11179094A IL111790A IL 111790 A IL111790 A IL 111790A IL 11179094 A IL11179094 A IL 11179094A IL 11179094 A IL11179094 A IL 11179094A IL 111790 A IL111790 A IL 111790A
- Authority
- IL
- Israel
- Prior art keywords
- amyloidogenic
- compound
- formula
- compounds
- amyloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/160,379 US6489355B2 (en) | 1993-12-01 | 1993-12-01 | Methods of inhibiting the effects of amyloidogenic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
IL111790A0 IL111790A0 (en) | 1995-01-24 |
IL111790A true IL111790A (en) | 1998-10-30 |
Family
ID=22576649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11179094A IL111790A (en) | 1993-12-01 | 1994-11-28 | Use of benzo [B] thiopines in the preparation of anti-amyloidogenic drugs |
Country Status (14)
Country | Link |
---|---|
US (1) | US6489355B2 (zh) |
EP (1) | EP0663209A3 (zh) |
JP (1) | JPH07188010A (zh) |
KR (1) | KR950016720A (zh) |
CN (1) | CN1109750A (zh) |
AU (1) | AU673961B2 (zh) |
CA (1) | CA2136789A1 (zh) |
CZ (1) | CZ293194A3 (zh) |
HU (1) | HUT72297A (zh) |
IL (1) | IL111790A (zh) |
NO (1) | NO944577L (zh) |
NZ (1) | NZ270008A (zh) |
UA (1) | UA26459C2 (zh) |
ZA (1) | ZA949404B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
JP2002518329A (ja) | 1998-06-16 | 2002-06-25 | イーライ・リリー・アンド・カンパニー | アセチルコリンレベルを増加させる方法 |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
CA2668744C (en) * | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
CN108186678A (zh) * | 2018-01-10 | 2018-06-22 | 天津科技大学 | 羟基化碳纳米管在制备抑制β-淀粉样蛋白聚集的药物的用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US5145892A (en) * | 1985-12-19 | 1992-09-08 | Chisso Corporation | Polypropylene resin composition |
US5075321A (en) | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
US4960815A (en) * | 1988-09-22 | 1990-10-02 | Warner-Lambert Company | Isotopically-labeled polycyclic amine derivatives |
US5081304A (en) * | 1988-09-22 | 1992-01-14 | Warner-Lambert Company | Isotopically-labeled polycyclic amine derivatives |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
GB9002834D0 (en) * | 1990-02-08 | 1990-04-04 | Ici America Inc | Compounds |
US5214063A (en) * | 1990-06-27 | 1993-05-25 | Adir Et Compagnie | 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors |
FR2663934B1 (fr) * | 1990-06-27 | 1994-06-03 | Adir | Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent. |
US5189041A (en) * | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5175164A (en) * | 1991-06-05 | 1992-12-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted indole or dihydroindole |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5192220A (en) * | 1992-01-31 | 1993-03-09 | Amp Inc. | Dual readout extended socket |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5288249A (en) * | 1992-09-02 | 1994-02-22 | Cooper Industries, Inc. | Base for cartridge lamp |
US5252524A (en) * | 1992-10-16 | 1993-10-12 | Corning Incorporated | Polarizing glasses |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
JP4111352B2 (ja) | 1996-05-21 | 2008-07-02 | 新日鐵住金ステンレス株式会社 | ステンレス鋼の高清浄化精錬法 |
-
1993
- 1993-12-01 US US08/160,379 patent/US6489355B2/en not_active Expired - Fee Related
-
1994
- 1994-11-28 CA CA002136789A patent/CA2136789A1/en not_active Abandoned
- 1994-11-28 IL IL11179094A patent/IL111790A/en active IP Right Grant
- 1994-11-28 UA UA94119085A patent/UA26459C2/uk unknown
- 1994-11-28 CZ CZ942931A patent/CZ293194A3/cs unknown
- 1994-11-28 ZA ZA949404A patent/ZA949404B/xx unknown
- 1994-11-28 NZ NZ270008A patent/NZ270008A/en unknown
- 1994-11-29 EP EP94308805A patent/EP0663209A3/en not_active Withdrawn
- 1994-11-29 AU AU79093/94A patent/AU673961B2/en not_active Ceased
- 1994-11-29 KR KR1019940031649A patent/KR950016720A/ko not_active Application Discontinuation
- 1994-11-29 NO NO944577A patent/NO944577L/no unknown
- 1994-11-29 HU HU9403422A patent/HUT72297A/hu unknown
- 1994-11-30 JP JP6296343A patent/JPH07188010A/ja active Pending
- 1994-11-30 CN CN94112880A patent/CN1109750A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0663209A2 (en) | 1995-07-19 |
AU7909394A (en) | 1995-06-08 |
NO944577D0 (no) | 1994-11-29 |
US20010051368A1 (en) | 2001-12-13 |
HUT72297A (en) | 1996-04-29 |
US6489355B2 (en) | 2002-12-03 |
CZ293194A3 (en) | 1995-07-12 |
ZA949404B (en) | 1996-05-28 |
HU9403422D0 (en) | 1995-02-28 |
CN1109750A (zh) | 1995-10-11 |
EP0663209A3 (en) | 1995-10-11 |
NO944577L (no) | 1995-06-02 |
AU673961B2 (en) | 1996-11-28 |
JPH07188010A (ja) | 1995-07-25 |
KR950016720A (ko) | 1995-07-20 |
IL111790A0 (en) | 1995-01-24 |
NZ270008A (en) | 1997-07-27 |
CA2136789A1 (en) | 1995-06-02 |
UA26459C2 (uk) | 1999-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5552415A (en) | Method of inhibiting Alzheimer's Disease | |
AU698389B2 (en) | Methods for inhibiting LDL oxidation and atheroclerosis | |
JPH10504572A (ja) | ウイルスの複製を阻害する方法 | |
US5663184A (en) | Methods of inhibiting CNS problems in post-menopausal women | |
US6489355B2 (en) | Methods of inhibiting the effects of amyloidogenic proteins | |
US5719191A (en) | 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease | |
AU716064B2 (en) | Methods of increasing nitric oxide synthesis | |
JPH11513665A (ja) | プラスミノーゲンアクチベーターインヒビター1の阻害方法 | |
MXPA97001528A (en) | Derivatives of 1, 1, 2, - trifenilbut-1-eno to treat alzhei's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |